AVB-620 is an intravenously administered in vivo fluorescent protease-activatable peptide that detects, marks, and diagnoses cancer.
AVB-620 has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis. A Phase 2 clinical trial for AVB-620 in breast cancer was initiated in June 2017. AVB-620 hopes to address a large unmet medical need as 20%-40% of breast cancer patients are subjected to additional surgeries due to incomplete removal of the primary tumor or lymph node metastases. AVB-620 displayed outstanding preclinical data with sensitivity of >95% in preclinical breast cancer models and 100% in ex vivo analysis of human breast cancer tissue.